Optimistic about China's pharmaceutical market, Roche plus code investment of $180 million

[
pharmaceutical enterprise network newsRecently, the Swiss pharmaceutical giant Roche announced that it will further increase its investment in the Suzhou Industrial Park Roche Diagnostics Asia-Pacific R & D center and production base, plans to increase total investment of US $ 180 million , the cumulative total investment of $ 479 million, the capital increase will further deepen the strategic layout of Roche diagnostics in China, once again confirms Roche diagnostics root in China, dedicated to the Chinese medical industry co-development for the benefit of long-term commitment to China and the Asia-Pacific patientsIt is understood, it is located in the Suzhou Industrial Park Roche Diagnostics Roche Diagnostics Asia-Pacific production base in the Asia-Pacific region's first production base and the world's eighth largest production baseAnd the new investment will be used for in vitro diagnostic reagents production and construction of various product lines and transfer projects including the organization of diagnostic reagents and staining platforms, including professional diagnostic reagentsIn fact, due to the increasingly large domestic drug market, as well as new medical reform in recent years to stimulate the pharmaceutical industry, especially in our country to accelerate access to innovative drugs, multinational pharmaceutical companies in the Chinese market positive performance to achieve strong growthAccording to the multinational pharmaceutical companies announced 2019 third quarter report shows that by Keytruda and nine-valent HPV vaccine drive, Merck Q3 performance in China soared 90%; Roche, AstraZeneca China earnings growth of 53% and 37%, respectively..and good growth momentum and further enhance the confidence of multinational pharmaceutical companies in the Chinese market, more and more multinational pharmaceutical companies and even the Chinese market as a "key pillar of future growth", investing in China have heated up enthusiasmCurrently, in addition to Roche, but is there more and more multinational pharmaceutical companies continue to accelerate the layout of the domestic marketexample, Boehringer Ingelheim has two factories in Shanghai Zhangjiang, but in April this year, the company says that respect, BIX's Digital Innovation Lab officially decided to head overseas branches organization based in Shanghai, China join hands to accelerate the pace of local creative talents together to find a breakthrough treatmentBIX laboratory in Shanghai branch will be formally completed in July this year, and work closely with the headquarters of Boehringer Ingelheim China and Germany BIX headquartersThe first phase of the project investment amounted to 3 million eurosThe next five years plans to invest 188 million euros in China2019 In December 2009, the new global CEOPaulHudson Sanofi also announced the company will stop developing new diabetes and cardiovascular disease drug, and plans to introduce more than 20 kinds of innovative drugs to China in 2025 and vaccines2019 In November 2009, the Novartis said in a statement, the operator decided to focus on Shanghai R & D center focused on expanding the size of the field early and late stage clinical development and clinical trials, thus speeding up the development of new drugsThe adjustment will affect the jobs of more than 100 research departments, internal Novartis will be adjustedIn addition, Novartis relevant person in charge told reporters earlier in the interview, also mentioned that the company expects 2019-- period 2023 to submit 50 new drug application in ChinaOverall, multinational pharmaceutical companies in the country in recent years, although subject to a series of medical reform policies, the market growth is slowing, layoffs, and other news cast it constantly, but China's huge population, and drugs growing demand for multinational pharmaceutical companies still have attractive terms, so in recent years or multinational pharmaceutical companies in the domestic market continues to overweightIndustry is expected in the future opportunities and challenges in the Chinese market, multinational pharmaceutical companies, or open a new chapter in the development.